We Help Companies Find New Sales Opportunities
Aesica is to create 100 new jobs at its Queenborough pharmaceuticals plant on the Isle of Sheppey over the next three years.
Aesica Pharmaceuticals has sold a majority stake in its Northumberland-based drug development business to private equity firm Silverfleet Capital.
Aesica Pharmaceuticals has acquired three manufacturing sites in Germany and Italy from UCB.
Aesica is planning to double the size of its R5 Pharmaceuticals factory and laboratory business at BioCity Nottingham, with the creation of up to 30 jobs.
Aesica has acquired three pharmaceutical manufacturing plants in Germany and Italy from UCB, which will double the total size of its Newcastle-based business.
Aesica is to build a new £3m pharmaceutical production facility at its Queenborough site in Kent by May 2011.
Aesica has acquired R5 Pharmaceuticals, the Nottingham-based pharmaceuticals manufacturer with 51 staff, for undisclosed terms.
Aesica is to invest £5m in the expansion of its pharmaceuticals research centre in Cramlington over the next three years, and is now looking to recruit up to 30 scientists.
Aesica has finalised the acquisition of the Abbott pharmaceuticals factory in Queenborough, Kent, securing the future of 450 staff.
Aesica is planning to create about 40 jobs at a new £10m pharmaceuticals outsourcing factory in Northumberland over the next few years, while 15 new jobs will be created at its North London factory by the end of the year.
Aesica is to acquire a pharmaceuticals factory at Ponders End in north London from Merck & Co for undisclosed terms, with the transfer of 74 staff and the creation of 20 new jobs over the next few months.